| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 05/11/2022 | 108.88% | Morgan Stanley | $10 → $8 | Maintains | Equal-Weight |
| 03/07/2022 | 161.1% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
| 02/15/2022 | 187.21% | Morgan Stanley | $24 → $11 | Maintains | Equal-Weight |
| 11/15/2021 | 526.63% | Morgan Stanley | $26 → $24 | Maintains | Equal-Weight |
| 08/09/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/09/2021 | 578.85% | Morgan Stanley | → $26 | Initiates Coverage On | → Equal-Weight |
| 08/09/2021 | 631.07% | Stifel | → $28 | Initiates Coverage On | → Buy |
| 08/09/2021 | 683.29% | JP Morgan | → $30 | Initiates Coverage On | → Overweight |
Rapid Micro Biosystems Questions & Answers
The latest price target for Rapid Micro Biosystems (NASDAQ: RPID) was reported by JP Morgan on August 16, 2022. The analyst firm set a price target for $0.00 expecting RPID to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Rapid Micro Biosystems (NASDAQ: RPID) was provided by JP Morgan, and Rapid Micro Biosystems downgraded their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rapid Micro Biosystems, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rapid Micro Biosystems was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
While ratings are subjective and will change, the latest Rapid Micro Biosystems (RPID) rating was a downgraded with a price target of $0.00 to $0.00. The current price Rapid Micro Biosystems (RPID) is trading at is $3.83, which is out of the analyst's predicted range.